PARK

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

Retrieved on: 
Thursday, November 9, 2023

Third Quarter 2023 Financial Results:

Key Points: 
  • Third Quarter 2023 Financial Results:
    Net loss for the third quarter ended September 30, 2023, was $43.2 million, compared to $51.1 million for third quarter 2022.
  • Third quarter 2023 net loss included a non-cash charge related to stock-based compensation of $6.1 million compared to $5.8 million for third quarter 2022.
  • Research and development expenses for the third quarter 2023 were $12.3 million, a decrease of $6.7 million compared to $19.0 million for third quarter 2022.
  • General and administrative expenses for the third quarter 2023 were $23.4 million, a decrease of $0.1 million compared to $23.5 million for third quarter 2022.

Oka, The Carbon Insurance Company™ Joins International Emissions Trading Association (IETA)

Retrieved on: 
Thursday, November 9, 2023

PARK CITY, Utah, Nov. 9, 2023 /PRNewswire/ -- Oka, The Carbon Insurance Company™ (Oka) has been accepted as a member of the International Emissions Trading Association (IETA), the leading trade association for international carbon markets.

Key Points: 
  • PARK CITY, Utah, Nov. 9, 2023 /PRNewswire/ -- Oka, The Carbon Insurance Company™ (Oka) has been accepted as a member of the International Emissions Trading Association (IETA), the leading trade association for international carbon markets.
  • Oka is the first dedicated carbon insurance company to join IETA.
  • Its members include standards and registries, project developers, technology providers, energy companies, financial institutions, and other business leaders across the carbon trading cycle.
  • IETA's recognition is a landmark step for Oka and a promising signal for specialist carbon insurance.

Robert D. Newman, NHC President and Director, Announces Retirement

Retrieved on: 
Wednesday, November 8, 2023

RESEARCH TRIANGLE PARK, N.C. , Nov. 8, 2023 /PRNewswire/ -- After nine years at the helm of the National Humanities Center (NHC), President and Director Robert D. Newman has announced his retirement. He will step down as director in July 2024. A search to hire his replacement will begin soon.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C. , Nov. 8, 2023 /PRNewswire/ -- After nine years at the helm of the National Humanities Center (NHC), President and Director Robert D. Newman has announced his retirement.
  • Robert Newman assumed leadership of the Center in 2015 and has overseen an array of initiatives expanding opportunities for humanities scholars and teachers.
  • His efforts have significantly raised the Center's profile as an important resource for scholars, educators, and other knowledge seekers.
  • Robert has rallied significant support for the Center and its programs, allowing the NHC to reach more scholars and teachers than at any time in its past.

Science 37 Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023

RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”), the industry-leading Metasite™, today reported its financial results for the quarter ended September 30, 2023.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), (“Science 37”), the industry-leading Metasite™, today reported its financial results for the quarter ended September 30, 2023.
  • Backlog was $163.1 million for the quarter ended September 30, 2023, compared to $170.4 million for the same period in 2022.
  • Science 37 anticipates cash burn in the fourth quarter of 2023 to be less than $6.4 million, and expects to exit 2023 with more than $50.0 million of cash on hand.
  • Science 37 will host a conference call on November 7, 2023, at 8:30 a.m. Eastern Time to discuss its third quarter 2023 financial results.

Asensus Surgical, Inc. Schedules Third Quarter Financial and Operating Results Conference Call for November 14, 2023

Retrieved on: 
Tuesday, November 7, 2023

RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient announced today that it plans to release 2023 third quarter financial and operating results after the market closes on Tuesday, November 14, 2023.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient announced today that it plans to release 2023 third quarter financial and operating results after the market closes on Tuesday, November 14, 2023.
  • The Company will host a conference call to discuss these results starting at 4:30 p.m.
  • To listen to the conference call on your telephone, please dial 1-888-886-7786 for domestic callers and 416-764-8658 for international callers, approximately ten minutes prior to the start time.
  • To access the live audio webcast or archived recording, use the following link https://ir.asensus.com/events-and-presentations .

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, November 6, 2023

The options and RSUs were granted as of October 31, 2023, as inducements material to each employee entering into employment with BioCryst.

Key Points: 
  • The options and RSUs were granted as of October 31, 2023, as inducements material to each employee entering into employment with BioCryst.
  • The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options have an exercise price of $5.49 per share, which is equal to the closing price of BioCryst common stock on the grant date.
  • The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

Asensus Surgical Announces Klinikum Idar-Oberstein Hospital in Germany to Initiate Senhance Surgery Program

Retrieved on: 
Monday, November 6, 2023

"We are pleased to collaborate with Klinikum Idar-Oberstein Hospital as they aim to enhance patient outcomes through advanced minimally invasive surgery.

Key Points: 
  • "We are pleased to collaborate with Klinikum Idar-Oberstein Hospital as they aim to enhance patient outcomes through advanced minimally invasive surgery.
  • The innovative features of the Senhance System, combined with the established laparoscopic approach, will bring valuable enhancements to the Idar-Oberstein Hospital," commented Anthony Fernando, President and CEO of Asensus Surgical.
  • "We look forward to working with Dr. Christos Zigouris and team to ensure the success of their team’s Senhance program."
  • “With the introduction of the Senhance program at Idar-Oberstein Hospital, we are raising the bar for patient care,” said Dr. med.

Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 6, 2023

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today reported its financial results for the third quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • ET ~
    RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today reported its financial results for the third quarter ended September 30, 2023 and provided a business update.
  • “We continued to see strong commercial performance with PEDMARK® in the third quarter demonstrated by net product revenue of $6.5 million representing 96% quarter over quarter growth.
  • The Company had gross profit of $6.2 million for the third quarter of 2023.
  • ET, to discuss the Company’s financial results from the third quarter, ended September 30, 2023, and provide a business outlook for the remainder of 2023.

BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

Retrieved on: 
Friday, November 3, 2023

A live webcast of the event will be available online in the investors section of the company website at www.biocryst.com .

Key Points: 
  • A live webcast of the event will be available online in the investors section of the company website at www.biocryst.com .
  • The team is excited to share our approach, and our expanded pipeline of new programs, at our R&D Day,” said Jon Stonehouse, president and chief executive officer of BioCryst.
  • The disease is caused by the deficiency of a natural inhibitor (SPINK5) of KLK5, a serine protease responsible for regulating skin shedding.
  • Netherton syndrome can be life threatening, especially during infancy when patients are vulnerable to dehydration and recurrent infections.

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®

Retrieved on: 
Friday, November 3, 2023

ALPHARETTA, Ga. and RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Clearside Biomedical, Inc. (Nasdaq: CLSD) today announced the entry into a license agreement enabling BioCryst to develop its investigational plasma kallikrein inhibitor, avoralstat, with Clearside’s SCS Microinjector® to deliver avoralstat directly to the back of the eye through the suprachoroidal space to treat patients with diabetic macular edema (DME).

Key Points: 
  • “Many DME patients are not effectively controlled with anti-VEGF therapy, so it is exciting to target plasma kallikrein by combining avoralstat with delivery into the suprachoroidal space using Clearside’s proprietary SCS Microinjector.
  • Avoralstat has high potency and low solubility, which are two characteristics important to achieving potential efficacy with reduced dosing frequency in the eye for DME patients.
  • Avoralstat was previously evaluated in an oral formulation in a Phase 3 clinical trial in patients with hereditary angioedema (HAE).
  • “Treating patients with DME by delivering avoralstat directly to the suprachoroidal space using the SCS Microinjector expands the reach of our proprietary SCS injection platform to a greater number of patients.